Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure

AIDS. 2010 Sep 10;24(14):2239-44. doi: 10.1097/QAD.0b013e32833c85d6.

Abstract

Objective: To identify risk factors for acute renal failure (ARF) in HIV-infected patients.

Design: Observational cohort study of HIV-infected patients attending a South London HIV centre between January 1999 and December 2008.

Methods: ARF was defined as a transient, more than 40% reduction in renal function as assessed by estimated glomerular filtration rate. Multivariate Poisson regression analysis was used to identify baseline and time-updated factors associated with ARF.

Results: The incidence of ARF was 2.8 (95% confidence interval 2.41-3.24) episodes per 100 person-years. We observed a stepwise increase in ARF incidence with time accrued at lower CD4 cell count and at lower estimated glomerular filtration rate, with adjusted incidence rate ratios of 1 (reference), 1.56 (0.97-2.48), 2.08 (1.11-3.91), 6.38 (3.18-12.78) and 10.29 (5.11-20.98) for CD4 cell counts of more than 350, 201-350, 101-200, 51-100 and of 50/microl or less, and 1 (reference), 1.46 (0.86-2.51), 4.19 (2.37-7.42) and 27.00 (16.13-44.95) for estimated glomerular filtration rate more than 90, 75-89, 60-74 and less than 60 ml/min, respectively. Ethnicity, hepatitis B or C coinfection, exposure to combination antiretroviral therapy with or without indinavir, tenofovir or atazanavir and HIV viraemia were not associated with ARF.

Conclusion: Current levels of immunodeficiency and renal function were independent predictors of HIV-associated ARF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / immunology*
  • Acute Kidney Injury / virology
  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adult
  • Atazanavir Sulfate
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Female
  • Glomerular Filtration Rate
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV Protease Inhibitors / administration & dosage*
  • Humans
  • Indinavir / administration & dosage*
  • London
  • Male
  • Oligopeptides / administration & dosage*
  • Organophosphonates / administration & dosage*
  • Pyridines / administration & dosage*
  • Risk Factors
  • Tenofovir

Substances

  • HIV Protease Inhibitors
  • Oligopeptides
  • Organophosphonates
  • Pyridines
  • Atazanavir Sulfate
  • Indinavir
  • Tenofovir
  • Adenine